Validation of two predictive models for survival in pulmonary arterial hypertension

European Respiratory Journal

Volumn 46, Issue 1, 2015, Pages 152-164

  Sitbon, Olivier ^a   Benza, Raymond L ^b   Badesch, David B ^c   Barst, Robyn J ^d   Elliott, C Gregory ^e   Gressin, Virginie ^f   Lemarié, Jean Christophe ^g   Miller, Dave P ^h   Rouzic, Erwan Muros Le ⁱ   Simonneau, Gérald ^a   Frost, Adaani E ^j   Farber, Harrison W ^k   Humbert, Marc ^a   McGoon, Michael D ^l  

^a BICÊTRE HOSPITAL   (France)

^b ALLEGHENY HEALTH NETWORK   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Columbia University College of Physicians and Surgns ^*  (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f Actelion Pharmaceuticals France   (France)

^g Effi Stat   (France)

^h ICON CLINICAL RESEARCH   (United States)

ⁱ ACTELION PHARMACEUTICALS LTD   (Switzerland)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT;

ADULT; ANOREXIGEN INDUCED PULMONARY HYPERTENSION; ARTICLE; COHORT ANALYSIS; DISEASE REGISTRY; EXTERNAL VALIDITY; FAMILIAL PULMONARY HYPERTENSION; FEMALE; FRENCH PULMONARY HYPERTENSION NETWORK REGISTRY; HAZARD RATIO; HUMAN; IDIOPATHIC PULMONARY HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; REGISTRY TO EVALUATE EARLY AND LONG TERM PULMONARY ARTERIAL HYPERTENSION DISEASE MANAGEMENT; RISK ASSESSMENT; STATISTICAL MODEL; SURVIVAL RATE; VALIDATION STUDY; AGED; ALGORITHM; CALIBRATION; FAMILIAL PRIMARY PULMONARY HYPERTENSION; HYPERTENSION, PULMONARY; INCIDENCE; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROBABILITY; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK; THEORETICAL MODEL;

ADULT; AGED; ALGORITHMS; CALIBRATION; COHORT STUDIES; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; MALE; MIDDLE AGED; MODELS, THEORETICAL; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK; SURVIVAL RATE;

EID: 84928964408     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00004414     Document Type: Article

References (40)

1. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: Suppl., 78S-92S.
2. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
3. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
4. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
5. Ghofrani HA, Barst RJ, Benza RL, et al. Future perspectives for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: Suppl., S108-S117.
6. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
7. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007; 30: 1103-1110.
8. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
9. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
10. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006; 28: 1195-1203.
11. Lau EM, Manes A, Celermajer DS, et al. Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward. Eur Heart J 2011; 32: 2489-2498.
12. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376-387.
13. Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 2012; 141: 354-362.
14. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
15. Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
16. Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 2007; 132: 373-379.
17. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-1093.
18. Thenappan T, Shah SJ, Rich S, et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010; 35: 1079-1087.
19. Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104-109.
20. McGoon MD, Krichman A, Farber HW, et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc 2008; 83: 923-931.
21. Sitbon O, Yaïci A, Rottat L, et al. The changing picture of patients with pulmonary arterial hypertension (PAH) in France. Eur Respir J 2011; 38: Suppl. 55, 4913.
22. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142: 448-456.
23. Cogswell R, Kobashigawa E, McGlothlin D, et al. Validation of the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL) pulmonary hypertension prediction model in a unique population and utility in the prediction of long-term survival. J Heart Lung Transplant 2012; 31: 1165-1170.
24. Kane GC, Maradit-Kremers H, Slusser JP, et al. Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest 2011; 139: 1285-1293.
25. McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev 2012; 21: 8-18.
26. McGinn TG, Guyatt GH, Wyer PC, et al. Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. JAMA 2000; 284: 79-84.
27. Miller DP, Gomberg-Maitland M, Humbert M. Survivor bias and risk assessment. Eur Respir J 2012; 40: 530-532.
28. Altman DG, Vergouwe Y, Royston P et al. Prognosis and prognostic research: validating a prognostic model. BMJ 2009; 338: b605.
29. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928-935.
30. Kremers WK. Concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time. Mayo Clinic Technical Report Series no. 80. 2007. www.mayo.edu/research/documents/biostat-80pdf/DOC-10027891 Date last accessed: December 16, 2013. Date last updated: April, 2007.
31. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
32. Escribano-Subias P, Blanco I, López-Meseguer M, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J 2012; 40: 596-603.
33. Lee WT, Ling Y, Sheares KK, et al. Predicting survival in pulmonary arterial hypertension in the UK. Eur Respir J 2012; 40: 604-611.
34. Fritz JS, Blair C, Oudiz RJ, et al. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest 2013; 143: 315-323.
35. Benza RL, Miller DP, Foreman AJ, et al. Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: A Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. J Heart Lung Transplant 2015; 34: 356-361.
36. McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013; 62: Suppl., D51-D59.
37. Badagliacca R, Pezzuto B, Poscia R, et al. Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral. J Heart Lung Transplant 2012; 31: 364-372.
38. Galiè N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403.
39. Benza RL, Miller DP, Frost A, et al. Analysis of the lung allocation score estimation of risk of death in patients with pulmonary arterial hypertension using data from the REVEAL Registry. Transplantation 2010; 90: 298-305.
40. Benza R, Gomberg-Maitland M, Frost AE, et al. Development of prognostic tools in pulmonary arterial hypertension: lessons from modern day registries. Thromb Haemost 2012; 108: 1049-1060.